Science News
Discover the news and inspiring materials from the world of biotechnology.
Mabion is a Champion of the 2025 International CDMO Leadership Award in Biologics
Mabion Wins as the Champion of the 2025 International CDMO Leadership Award in Biologics! This achievement is a testament to our commitment to innovation, reliability, and excellence in biologics development and manufacturing. We extend our heartfelt thanks to our clients for their trust and collaboration – your success is our success!
Learn more
Mabion’s Fill & Finish services in Contract Pharma Magazine
The Fill & Finish stage of pharma manufacturing may not make headlines, but it is the final crucial step – the point where all the work behind a new drug either comes together or falls apart due to contamination, inefficiencies, or regulatory setbacks. Right now, the demand for high-quality, adaptable fill-finish services is soaring. Mabion Biologics CDMO offer the expertise, flexibility, and advanced technology that pharmaceutical companies need to navigate today’s challenges. Explore our Production Division Manager’s expertise on the role of compliance in today’s filling and finishing landscape in Contract Pharma.
Learn more
Dyskinesias in Parkinson’s Disease: Promising New Treatment Approach
CPL’36 Phase II clinical trial results reinforce the potential of PDE10A inhibition as a new therapeutic strategy for managing dyskinesias and improving the quality of life for individuals with Parkinson’s disease.
Learn more
Mabion is a Finalist in the CDMO Leadership Awards 2025 in the Biologics category
Winning the 2025 CDMO Leadership Awards strengthens Mabion’s reputation as a high quality CDMO, making us more attractive to potential clients. The recognition will boost our industry presence, opening doors to new business opportunities and partnerships.
Learn more
How long might CAR-T cell therapy work?
In a remarkable medical milestone, a woman has remained cancer-free for an unprecedented 19 years following a pioneering CAR-T cell therapy administered during her childhood. This groundbreaking case offers renewed hope for the long-term efficacy of CAR-T cell treatments in combating rare pediatric cancers.
Learn more
Mabion Wins Best of Industry Insights Award for Biologics Outsourcing Article in Outsourced Pharma Best Of 2024
Mabion SMEs’s article has been awarded Best of Industry Insights in the Biologics Outsourcing category of the Outsourced Pharma Best Of 2024 awards.
Learn more
FDA approves first medication for obstructive sleep apnea: Eli Lilly’s Zepbound GLP-1 agonist
The FDA has approved Eli Lilly’s Zepbound (tirzepatide) as the first-ever medication for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity, providing a pharmacological alternative to CPAP machines and surgery.
Learn more
Biocon’s Yesintek receives EMA and FDA approval as the next ustekinumab biosimilar
Yesintek, a biosimilar to ustekinumab developed by Biocon, has received approval from both the EMA and FDA, joining other ustekinumab biosimilars like Amgen’s Wezlana and Alvotech’s Selarsdi.
Learn more